Open access
Sep 2026
Biparatopic targeting of CD38 using CD38-specific trimeric antibody recruiters improves cytotoxicity against multiple myeloma
Biparatopic targeting of CD38 using CD38-STARs represents a promising strategy for the treatment of MM, including the rare cases in which daratumumab fails to bind due to CD38 mutations.
H. Risch, A. J. Gebhardt, Niklas Hagen et al.
· Frontiers in Immunology · 0 citations